Detection of Dysbiosis and Increased Intestinal Permeability in Brazilian Patients with Relapsing-Remitting Multiple Sclerosis

Autor(es):Mostrar menos -

Pellizoni, Felipe Papa ; Leite, Aline Zazeri ; Rodrigues, Nathalia de Campos ; Ubaiz, Marcelo Jordao ; Gonzaga, Marina Ignacio ; Takaoka, Nauyta Naomi Campos ; Mariano, Vania Sammartino ; Omori, Wellington Pine ; Pinheiro, Daniel Guariz ; Matheucci Junior, Euclides ; Gomes, Eleni ; Oliveira, de Gislane Lelis Vilela

• Tipo de documento: Artigo Científico
• Fonte: INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH; v. 18, n. 9, p. 17-pg., 2021-05-01.

Resumo

Dysbiosis, associated with barrier disruption and altered gut-brain communications, has been associated with multiple sclerosis (MS). In this study, we evaluated the gut microbiota in relapsing-remitting patients (RRMS) receiving disease-modifying therapies (DMTs) and correlated these data with diet, cytokines levels, and zonulin concentrations. Stool samples were used for 16S sequencing and real-time PCR. Serum was used for cytokine determination by flow cytometry, and zonulin quantification by ELISA. Pearson's chi-square, Mann-Whitney, and Spearman's correlation were used for statistical analyses. We detected differences in dietary habits, as well as in the gut microbiota in RRMS patients, with predominance of Akkermansia muciniphila and Bacteroides vulgatus and decreased Bifidobacterium. Interleukin-6 concentrations were decreased in treated patients, and we detected an increased intestinal permeability in RRMS patients when compared with controls. We conclude that diet plays an important role in the composition of the gut microbiota, and intestinal dysbiosis, detected in RRMS patients could be involved in increased intestinal permeability and affect the clinical response to DTMs. The future goal is to predict therapeutic responses based on individual microbiome analyses (personalized medicine) and propose dietary interventions and the use of probiotics or other microbiota modulators as adjuvant therapy to enhance the therapeutic efficacy of DMTs. (AU)

• Processo FAPESP: 16/50204-0 - Sequenciamento de DNA de segunda geração (NGS) aplicado ao diagnóstico em microbiologia clínica
• Beneficiário: Nathalia de Campos Rodrigues
• Modalidade de apoio: Auxílio à Pesquisa - Pesquisa Inovativa em Pequenas Empresas - PIPE
• Processo FAPESP: 17/04508-0 - Análise metagenômica da microbiota fecal de pacientes com esclerose múltipla e correlação com a síntese de vitaminas B e K
• Beneficiário: Aline Zazeri Leite
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 16/05062-2 - Caracterização da microbiota intestinal isolada das fezes de pacientes com esclerose múltipla e correlação com citocinas do padrão Th17
• Beneficiário: Felipe Papa Pellizoni
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 21/03866-5 - Detecção de disbiose e aumento da permeabilidade intestinal em pacientes com esclerose múltipla surto-remissiva no Brasil
• Beneficiário: Eleni Gomes
• Modalidade de apoio: Auxílio à Pesquisa - Publicações científicas - Artigo